| Drug Name |
Ozanimod |
| Drug ID |
BADD_D02580 |
| Description |
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.[L12573,L12582] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382]
MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting.[A189336]
In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342] |
| Indications and Usage |
Ozanimod is indicated for adults in the treatment of relapsing forms of MS, which may include relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive MS.[L12582] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA38 |
| DrugBank ID |
DB12612
|
| KEGG ID |
D10968
|
| MeSH ID |
C000607776
|
| PubChem ID |
52938427
|
| TTD Drug ID |
D07EDB
|
| NDC Product Code |
Not Available |
| UNII |
Z80293URPV
|
| Synonyms |
ozanimod | RPC1063 |
